Vaccine最新文献

{"title":"Routine vaccination rates globally: A continuing and alarming situation","authors":"Helena C. Maltezou , Snezana Medic , Dimitrios C. Cassimos , Evgnosia Effraimidou , Gregory A. Poland","doi":"10.1016/j.vaccine.2025.127269","DOIUrl":"10.1016/j.vaccine.2025.127269","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127269"},"PeriodicalIF":4.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo","authors":"Kevin Liaw ,&nbsp;Kylie M. Konrath ,&nbsp;Abigail R. Trachtman ,&nbsp;Nicholas J. Tursi ,&nbsp;Ebony N. Gary ,&nbsp;Cory Livingston ,&nbsp;Kaitlyn Flowers ,&nbsp;Jacqueline D. Chu ,&nbsp;Casey E. Hojecki ,&nbsp;Niklas Laenger ,&nbsp;Madison E. McCanna ,&nbsp;Colby J. Agostino ,&nbsp;Neethu Chokkalingam ,&nbsp;Kelly Bayruns ,&nbsp;Sinja Kriete ,&nbsp;Amber Kim ,&nbsp;Joyce Park ,&nbsp;Cara Monastra ,&nbsp;Lucas A. Pardo ,&nbsp;Sarah Jenison ,&nbsp;David B. Weiner","doi":"10.1016/j.vaccine.2025.127231","DOIUrl":"10.1016/j.vaccine.2025.127231","url":null,"abstract":"<div><div>Current influenza vaccines induce mostly strain-specific immunity necessitating annual reformulation and dosing. Here, we developed an improved seasonal influenza vaccine based on A/H1N1/Wisconsin/588/2019. We designed a DNA-launched self-assembling nanoparticle that displayed seven Wisconsin/588/2019 hemagglutinin (HA) head domains (WI19-7mer). WI19-7mer nanovaccine improved heterologous HAI titers and CD8+ cellular responses in mice than DNA encoded HA trimer (WI19 HA). In human antibody repertoire mice, WI19-7mer induced superior breadth to a diverse panel of H1 HAs compared to WI19 HA immunized animals. Cross-reactive HAI titers were maintained better in mice immunized with WI19-7mer than WI19 HA. The WI19-7mer induced improved antibody binding breadth and provided superior protection in a heterologous challenge compared to challenge-matched HA trimer. Addition of the cytokine adjuvant (CTACK) to WI19-7mer significantly improved breadth, HAI, peripheral responses, and protection in heterologous challenge. These data demonstrate that combining nucleic acid delivery, immune focusing, low valency nanoparticle, and mucosal adjuvant for enhanced vaccine effectiveness has broader applications for other viruses.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127231"},"PeriodicalIF":4.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 vaccination by implementation timing and coverage rate in relation to misinformation prevalence in Japan","authors":"Yuki Furuse ,&nbsp;Takahiro Tabuchi","doi":"10.1016/j.vaccine.2025.127273","DOIUrl":"10.1016/j.vaccine.2025.127273","url":null,"abstract":"<div><div>COVID-19 vaccines have saved many lives during the pandemic. However, the implementation strategy of vaccination in some countries may not have been ideal. In this study, we investigated the impact of vaccination on COVID-19 mortality in counterfactual scenarios for different vaccine implementation timings and coverage in Japan. To do so, we developed a mathematical model to predict the number of COVID-19 deaths using weekly data on COVID-19 cases, vaccination coverage, vaccine effectiveness, and the proportion of SARS-CoV-2 variants. We also reanalyzed survey data from our previous study about the prevalence of misinformation beliefs and attitudes toward COVID-19 vaccination, in order to build counterfactual scenarios in which we had managed misinformation better or worse. In Japan, the COVID-19 death toll was 14,994 in 2021 before the emergence of the Omicron variant in December. Counterfactual scenario simulations using the mathematical model revealed that 30,117 deaths were averted by vaccination in 2021, considering the direct and indirect effects of vaccines. If we had failed to manage the influence of misinformation, vaccination coverage would have dropped from 83.4 % to 76.6 %. And there would have been 1020 more deaths. The death toll could have decreased by 431 in a scenario for better misinformation management, assuming vaccination coverage of 88.0 %. Three-month delayed vaccination implementation would have increased the death toll by 22,216, whereas three-month early implementation would have averted 7003 deaths. Therefore, implementation timing had a stronger effect than vaccination coverage. This study highlights the importance of assessing vaccination strategies from the perspective of misinformation management and timing to start vaccination rollout.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127273"},"PeriodicalIF":4.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144098736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and clinical features of breakthrough varicella in the 9 years after universal vaccination began in Japan","authors":"Fumihiko Hattori ,&nbsp;Yuki Higashimoto ,&nbsp;Hiroki Miura ,&nbsp;Yoshiki Kawamura ,&nbsp;Akiko Yoshikawa ,&nbsp;Masaru Ihira ,&nbsp;Tetsushi Yoshikawa ,&nbsp;Nagoya VZV Study Group","doi":"10.1016/j.vaccine.2025.127274","DOIUrl":"10.1016/j.vaccine.2025.127274","url":null,"abstract":"<div><h3>Objective</h3><div>To elucidate the trends and clinical features of virologically diagnosed breakthrough varicella (BV) 9 years after implementation of the universal vaccination program in Japan.</div></div><div><h3>Patients and methods</h3><div>Study participants were patients with suspected varicella less than 15 years of age who visited 1 of 15 pediatric clinics in the Nagoya VZV Study Group between September 2015 and August 2023. Practitioners collected patient samples and information such as background characteristics, clinical symptoms, and immunization status. All patients had varicella confirmed by real-time polymerase chain reaction assays.</div></div><div><h3>Results</h3><div>Of 719 patients with suspected varicella, 512 had laboratory-diagnosed varicella and available information on vaccination status. They were divided into 3 groups: 167 with natural varicella, 250 with BV and 1 dose of vaccine, and 95 with BV and 2 doses. The monthly number of patients with varicella decreased gradually during the observation period. Typical seasonal peaks were observed until the 2019–2020 season. The proportion of patients with BV, particularly BV after 2 doses of vaccine, gradually increased. Patients with BV and 2 doses had a significantly lower median age (5 years) than those with 1 dose (6 years) (<em>p</em> &lt; 0.001). The transmission route for BV was unknown in approximately 30–50 % of patients. Duration of fever was significantly longer (<em>p</em> = 0.0138) and the number of skin eruptions was also significantly higher (<em>p</em> = 0.0013) in the 1-dose group than in the 2-dose group.</div></div><div><h3>Conclusions</h3><div>Although the number of pediatric patients with varicella declined after implementation of national immunization with 2 doses of varicella vaccine, the proportion of patients with BV, especially those who received 2 doses, gradually increased. Clinical symptoms were significantly milder in patients with BV and 2 doses. Laboratory diagnosis of varicella is becoming increasingly important due to an increase in the proportion of patients with BV who have mild symptoms.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127274"},"PeriodicalIF":4.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144098737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guided design for the development of an evolution-proof influenza vaccine","authors":"Lauren Myburgh ,&nbsp;Karlijn van Loon ,&nbsp;Elisabeth J.M. Huijbers ,&nbsp;Judy R. van Beijnum ,&nbsp;Colin A. Russell ,&nbsp;Arjan W. Griffioen","doi":"10.1016/j.vaccine.2025.127281","DOIUrl":"10.1016/j.vaccine.2025.127281","url":null,"abstract":"<div><div>Influenza remains a significant public health concern, particularly among high-risk populations, due to its capacity to cause annual epidemics and potentially trigger global pandemics. Despite the availability of countermeasures such as vaccines and antiviral treatments, their effectiveness is hindered by factors such as resistance development with manufacturing of the influenza vaccine still heavily relying on decades-old technologies. This review therefore examines the mechanisms by which influenza viruses evade host immunity and evaluates current and emerging approaches to enhance vaccine-mediated protection. Advances targeting the conserved hemagglutinin (HA) stem, incorporating multiple HA subtypes, and the use of adjuvants are discussed, alongside increased attention to neuraminidase (NA) and other viral components as immunogenic targets. Strategic epitope prediction, through glycan masking, evolutionary forecasting, and consensus sequence design, offer promising frameworks for rational vaccine design. Furthermore, delivery platforms, including recombinant protein, mRNA, and conjugate vaccines are explored for their potential to elicit broad and durable immunity. Collectively, these developments highlight a multifaceted approach towards the design of effective interventions against this persistent healthcare challenge.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127281"},"PeriodicalIF":4.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network","authors":"Tiffany Fitzpatrick ,&nbsp;Peter Yamoah ,&nbsp;David Summerby-Murray ,&nbsp;Juthaporn Cowan ,&nbsp;Manish Sadarangani ,&nbsp;Alissa Wright ,&nbsp;Sara Belga ,&nbsp;Cora Constantinescu ,&nbsp;Alex Carignan ,&nbsp;Athena McConnell ,&nbsp;Karina A. Top ,&nbsp;on behalf of the Canadian Immunization Research Network Investigators","doi":"10.1016/j.vaccine.2025.127254","DOIUrl":"10.1016/j.vaccine.2025.127254","url":null,"abstract":"<div><div>Neurological adverse events have been reported rarely following COVID-19 vaccination. This study describes the characteristics of adolescents and adults assessed in the Canadian Special Immunization Clinic (SIC) Network for neurological adverse events following immunization (AEFIs) and outcomes of revaccination. Among 60 participants enrolled from January 2021 to February 2023, paresthesia/anesthesia was the most common diagnosis (15/60; 25.0 %), followed by Bell's Palsy (6/60; 10.0 %). Twenty-eight percent (17/60) of participants were hospitalized for their AEFI. Revaccination was recommended to 32/46 (69.6 %) participants due for subsequent doses when assessed in the SIC. Twenty-three participants were revaccinated and 4/23 (17.4 %) had recurrent symptoms of the AEFI; three were milder than the first event and none required hospitalization. Revaccination was generally safe in selected patients after a neurological AEFI. Expert assessment of patients with neurological AEFIs may help to support further vaccination.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127254"},"PeriodicalIF":4.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144098731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months","authors":"Eliel Nham ,&nbsp;Joon Young Song ,&nbsp;Jang Wook Sohn ,&nbsp;Won Suk Choi ,&nbsp;Seong-Heon Wie ,&nbsp;Jacob Lee ,&nbsp;Jin-Soo Lee ,&nbsp;Hye Won Jeong ,&nbsp;Joong Sik Eom ,&nbsp;Yu Jung Choi ,&nbsp;Jin Gu Yoon ,&nbsp;Ji Yun Noh ,&nbsp;Hee Jin Cheong ,&nbsp;Woo Joo Kim","doi":"10.1016/j.vaccine.2025.127275","DOIUrl":"10.1016/j.vaccine.2025.127275","url":null,"abstract":"<div><h3>Background</h3><div>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, with each new strain becoming immunologically distinct from previous strains. The updated vaccine formulation for the 2023/24 season contained the mRNA of the XBB.1.5 sublineage. As the coronavirus disease-2019 (COVID-19) has become an endemic disease, a yearly assessment of updated COVID-19 vaccines is necessary.</div></div><div><h3>Methods</h3><div>This test-negative case-control study included patients who underwent COVID-19 testing between November 2023 and April 2024, and between July and August 2024, at eight university hospitals. To assess the change in VE over time, the study was divided into periods 1 (November–December 2023), 2 (January–April 2024), and 3 (July–August 2024) to assess the change of vaccine effectiveness (VE). VE (against laboratory-confirmed COVID-19 and COVID-19-related hospitalization) was calculated using adjusted odds ratios (OR) derived from multivariable logistic regression models.</div></div><div><h3>Results</h3><div>A total of 6198 patients were included (1671, 1811, and 2716 in period 1, 2, and 3, respectively), out of which 1115 (18.0%) underwent XBB.1.5 monovalent vaccination. The adjusted VE against laboratory-confirmed COVID-19 during each study period was 57.1% (95% confidence interval [CI]: 38.0–70.6, <em>p</em> &lt; 0.001), 18.8% (95% CI -4.7–37.2, <em>p</em> = 0.110), and 3.3% (95% CI -15.4–19.1, <em>p</em> = 0.707), respectively. The corresponding statistics against COVID-19-related hospitalization were 74.0% (95% CI 40.7–78.6, p &lt; 0.001), 34.2% (−6.8–46.4, <em>p</em> = 0.114), and 26.1% (4.7–42.8, <em>p</em> = 0.020), respectively.</div></div><div><h3>Conclusion</h3><div>Despite waning VE against laboratory-confirmed COVID-19 over time, XBB.1.5 mRNA vaccines conferred sustained protection against COVID-19-related hospitalizations throughout the year.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127275"},"PeriodicalIF":4.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with HPV vaccine hesitancy: A nationally representative cross-sectional study","authors":"Lygia Maria Costa Soares ,&nbsp;Ana Elza Oliveira de Medonça ,&nbsp;Dyego Leandro Bezerra de Souza ,&nbsp;Ariane Vieira Carvalho ,&nbsp;Matheus Gonçalves Flores ,&nbsp;Avelar Macedo Neto ,&nbsp;Diocésio Alves Pinto de Andrade ,&nbsp;Angélica Nogueira Rodrigues","doi":"10.1016/j.vaccine.2025.127278","DOIUrl":"10.1016/j.vaccine.2025.127278","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;HPV related tumors continue to be a global leading cause of cancer mainly due to cervical cancer (CC) burden. In Brazil, CC is the third most common cancer and the fourth highest cancer mortality rate among women. HPV vaccine mass immunization represents the current most promising intervention for CC prevention. It was first implemented in the Brazilian public health system in 2014, however, despite a history of excellent coverage for other vaccines, HPV vaccine uptake is below the necessary threshold for CC elimination. Identifying the factors that influence HPV vaccine hesitancy is an essential step to further develop strategies to improve vaccination coverage.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;The aim of this study is to provide insights into whether or not Brazilians are resistant to HPV vaccination and to determine the factors and variables that influence this decision.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This is a population-based cross-sectional study which used quantitative methodology through personal interviews. A total of 2010 interviews were planned to result in error margins of 2 percentage points, more or less considering a 95 % confidence level, encompassing all five Brazilian regions. Cities of different sizes and complexities were included in the sample, as capitals and cities in both metropolitan and rural areas. The research was carried out with the Brazilian population aged 16 and over, interviewees were approached at points of population flow.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Between June 12th and 16th 2023, a total of 2010 personal interviews were done, with participants from all five Brazilian regions. The prevalence of vaccine resistance was 5.97 % (95 % confidence interval [CI], 4.93–7.23) among those interviewed. A multivariate analysis demonstrated greater resistance to the vaccine among men (prevalence ratios (PR): 1.58; 95 %CI 1.06–2.34; &lt;em&gt;p:&lt;/em&gt; 0.023) and residents in the South region of the country (PR: 1.77; 95 %CI, 1.06–2.94; &lt;em&gt;p:&lt;/em&gt; 0.028). The three main reasons for refusing the vaccine reported by the participants were: lack of knowledge about the HPV vaccine; difficulty in accessing the vaccine; and lack of vaccine prescription by health professionals. Safety was the main reason not to vaccinate, cited by 10 %.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Despite HPV vaccine availability in Brazil at the public health system, vaccination coverage remains below the target for both genders. However, according to this analysis, there is a low rate of HPV vaccination hesitancy in the country, being lack of knowledge, difficulty in accessing the vaccine and lack of vaccine prescription by health professionals the main obstacles to adequate adherence. The COVID-19 pandemic doesn't seem to have affected HPV vaccination resistance in the country. Proper strategies for vaccine implementation, including school-based programs, patient-provider communication and education, and i","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127278"},"PeriodicalIF":4.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine hesitancy among Dutch parents of newborn children and its associated characteristics, values and uptake of vaccines","authors":"Daphne Bussink-Voorend ,&nbsp;Marlies E.J.L. Hulscher ,&nbsp;Reinier Akkermans ,&nbsp;André Krom ,&nbsp;Jeannine L.A. Hautvast","doi":"10.1016/j.vaccine.2025.127244","DOIUrl":"10.1016/j.vaccine.2025.127244","url":null,"abstract":"<div><div>The acceptance of routine childhood vaccinations gradually declined in the Netherlands. We aimed to assess the prevalence of vaccine hesitancy (VH), measured with the vaccine hesitancy assessment tool, associated characteristics, values and prospective vaccine uptake among parents.</div><div>A cross-sectional study was conducted, in which parents of children under three months completed a questionnaire. We analyzed associations between VH and characteristics, represented as adjusted odds ratios (aORs). Value scores were compared between participants who did and did not report VH, using an independent sample <em>t</em>-test. We subsequently calculated a relative risk (RR) to analyze the association between reported VH and vaccine uptake according to the recommended schedule at 6 months of age.</div><div>We included 533 parents and found that 27 % of parents reported VH in their decision about routine childhood vaccines. Having a lower education level (aOR 2.13, CI 1.26–3.60), intermediate vaccination intention (aOR 6.23, CI 2.79–13.92) and a religious or anthroposophical life philosophy (aOR 1.76, CI 1.06–2.93) were positively associated with VH. Age (aOR 0.92, CI 0.87–0.97) was negatively associated with VH. Additionally, parents who reported VH emphasized the value vaccine risks (<em>p</em> = 0.003) more and the values benevolence (<em>p</em> &lt; 0.001) and disease prevention (<em>p</em> &lt; 0.001) less. Additionally, the RR for children not being vaccinated according to schedule was 2.5 (CI 1.05–5.77) among parents reporting VH compared to parents who did not.</div><div>In conclusion, parents who reported VH were more likely to be less educated and younger, have a religious or anthroposophical life philosophy and were less certain about their vaccination intentions. Their children were more likely not to have been vaccinated according to the recommended schedule. We recommend further efforts to support parents in their decision-making about vaccination, to focus on younger and less educated parents, and pay attention to values important in their decision.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127244"},"PeriodicalIF":4.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144098735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women","authors":"Deborah Lupton ,&nbsp;Tyson Whitten ,&nbsp;Alvin Kuowei Tay ,&nbsp;Kristen Beek ,&nbsp;Melissa Green ,&nbsp;Fatima Hassoun ,&nbsp;Batool Moussa ,&nbsp;Derrick Silove ,&nbsp;Susan Rees","doi":"10.1016/j.vaccine.2025.127251","DOIUrl":"10.1016/j.vaccine.2025.127251","url":null,"abstract":"<div><h3>Background</h3><div>Hesitancy about the COVID-19 vaccine in high-income countries can be caused by diverse psychological and social factors. Few studies on vaccine concerns have examined the interplay of the effects of mental disorders, social and economic factors, gender and refugee status. To investigate these issues, this article reports findings from the 2023 wave of a longitudinal study involving 709 women who are mothers of young children in Australia, both refugees and Australian-born.</div></div><div><h3>Methods</h3><div>Respondents were asked if they had any worries or fears about receiving the COVID-19 vaccine. In previous waves they completed standardized assessments of mental health and sociodemographic factors. An open-ended question provided insights into the reasons for self-reported vaccine concerns. Descriptive statistics and binary logistic regression analyses were conducted, and demographic adjusted logistic regression undertaken separately for Australian-born and refugee women. Formal comparisons of effect sizes between Australian-born and refugee women were performed, with Cohen's <em>d</em> quantifying the magnitude of these differences. Qualitative responses were coded by topic and ranked by frequency.</div></div><div><h3>Findings</h3><div>More than half of the respondents reported worries about receiving a COVID-19 vaccine. Concerns were significantly higher for younger age women, those with a lower educational level and those with a history of mood disorder, panic disorder or separation anxiety disorder. Vaccine hesitancy was associated with poorer quality of life, living difficulties and disability among refugee women only. Separation anxiety disorder and a younger age were associated with an increased odds among Australian-born women only. The newness of the vaccine and concern about side effects were the greatest concerns among respondents who reported hesitancy.</div></div><div><h3>Conclusions</h3><div>Young mothers with mental health problems and lower education need to be sensitively targeted to improve COVID-19 vaccine uptake. Mental health and public health professionals need to be aware of differences reported for women from refugee background. Improved quality of life and economic status will increase vaccine uptake among socioeconomically challenged communities.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"58 ","pages":"Article 127251"},"PeriodicalIF":4.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144084005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}